An experimental immune-modulating therapy called KROS 101 was able to activate immune cells to kill glioma cells in laboratory experiments, according to new preclinical…
Glioma
The Lundin Cancer Fund has donated $4 million to the Canadian Cancer Society to create the Glioblastoma Research Program, a five-year initiative to…
A signaling molecule released by blood vessel cells prompts cancer cells to grow and become resistant to treatment in glioblastoma, an aggressive type of…
The U.S. Food and Drug Administration (FDA) has approved FoundationOne CDx, Foundation Medicine’s companion diagnostic test to help identify if patients with pediatric low-grade…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…
Chimerix has submitted an application asking the U.S. Food and Drug Administration (FDA) to approve its oral therapy dordaviprone as a treatment for recurrent…
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to the anti-cancer agent THIO as a potential treatment for an uncommon…
Treovir has launched a Phase 2 clinical trial to assess the safety and efficacy of G207, an experimental virus-based therapy, for pediatric recurrent high-grade…
Researchers have uncovered genetic changes that may explain why certain brain tumors, known as gliomas, that are associated with IDHÂ gene mutations start off as…
